Levels of urinary OAB biomarker and voiding symptom score in bladder cancer patients recieving intravesical BCG therapy

Levels of urinary OAB biomarker and voiding symptom score in bladder cancer patients recieving intravesical BCG therapy - Urinary biomarker study of BCG-induced OAB

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011569

Enrollment

Registered

2013-09-01

Start date

2013-08-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overactive bladder

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: High-risk nonmuscle-invasive bladder cancer patients receiving intravesical BCG therapy after TURBT

Exclusion criteria

Exclusion criteria: Residual urine >100ml Urinary infection Gross hematuria

Design outcomes

Primary

Measure	Time frame
Validated questionnaire such as OABSS, IPSS and CLSS. Urinary NGF and BDNF levels.	—

Countries

Japan

Contacts

Public ContactKatsura Ishioka

Keio University School of Medicine Department of Urology

katsuran-h@a5.keio.jp03-3353-1211

Outcome results